Flash Electroretinography Parameters and Parkinson's Disease.

BACKGROUND: Parkinson's disease (PD) is known to affect retinal structure and activity. As such, retinal evaluations may be used to develop objective and possibly early PD diagnostic tools. OBJECTIVE: The aim of this study was to investigate the effects of Parkinson's disease (PD) manifestation and treatment on retinal activity. METHODS: Data were collected on 21 participants diagnosed with PD, including the number of medications taken, clinical scales and flash electroretinography (fERG) measurements, under light-adapted and dark-adapted conditions. The fERG parameters measured included a-wave and b-wave amplitude and implicit time (i.e., latency). First, we investigated correlations between symptom measure scores and the fERG parameters. Next, we divided participants into two groups based on their antiparkinsonian medication load and analyzed differences between these groups' fERG parameters. RESULTS: fERG parameters were strongly correlated with a number of clinical variables, including motor and non-motor symptoms and age at PD onset. Photoreceptor cell implicit time was longer among participants taking one or less antiparkinsonian medication as compared to those taking two or more. However, overall there was not strong evidence of a relationship between the number of antiparkinsonian medications taken and the fERG parameters. CONCLUSION: Findings suggest that fERG may be a useful, non-intrusive measure of retinal, and, perhaps overall CNS function, in PD. However, additional studies in larger samples are needed to clarify this association.

People with current major depression resemble healthy controls on flash Electroretinogram indices associated with impairment in people with stabilized schizophrenia.

Flash electroretinography (fERG) has been used to identify anomalies in retinal functioning in several psychiatric disorders. In schizophrenia (SCZ), fERG abnormalities are reliably observed, but findings from studies of major depressive disorder (MDD) have been less consistent. In this study, fERG data were recorded from MDD patients in a current major depressive episode (n = 25), and compared to data from SCZ patients (n = 25) and healthy controls (HC; n = 25), to determine the degree to which fERG anomalies in acute MDD overlap or contrast with those observed in stabilized (though not symptom free) SCZ. The primary variables of interest were a-wave (photoreceptor activity), b-wave (bipolar-Müller cell activity), and photopic negative response (PhNR; ganglion cell activity) amplitudes and implicit times. Across most conditions, there were no significant differences between the MDD and HC groups in a- or b-wave response, but the SCZ group consistently demonstrated reduced amplitudes. Interestingly, MDD patients demonstrated an increase in photopic a-wave implicit time relative to SCZ patients, and a decrease in PhNR implicit time relative to controls. Correlations between BDI-II scores and fERG metrics were not significant for either patient group. Overall, these data indicate that, using an fERG protocol that distinguishes SCZ patients from controls, MDD patients experiencing a current depressive episode closely resemble healthy controls in their fERG responses. Therefore, MDD-related fERG changes may be more subtle than those observed in SCZ and detectable only with larger sample sizes than we employed and/or using a different set of fERG test parameters.